News

Public · Published

Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer

Agenus announced that Nature Medicine published results from the investigator-sponsored Phase 2 UNICORN trial of preoperative botensilimab alone or with balstilimab in resectable, locally advanced colon cancer. The trial enrolled 56 patients; among 14 with pMMR/MSS disease given the combination, 36% had a major pathologic response and 29% had no viable tumor at surgery.

Published:

Updated:

What happened

Agenus announced that Nature Medicine published results from the investigator-sponsored Phase 2 UNICORN trial of preoperative botensilimab alone or with balstilimab in resectable, locally advanced colon cancer. The trial enrolled 56 patients; among 14 with pMMR/MSS disease given the combination, 36% had a major pathologic response and 29% had no viable tumor at surgery.

Confirmed

Global impact / market context

The reported tumor responses provide clinical evidence for Agenus’s drug combination in a defined colon cancer group, but the evidence comes from only 14 treated patients in a non-randomized study. Further results and testing would determine whether these findings translate into reliable patient benefit and commercial opportunity.

Analyst inference

Publication in a peer-reviewed journal makes the trial findings accessible, but does not establish that the treatment is approved or superior to other care. Because the study included four small, non-randomized groups, investors have limited grounds to judge broader effectiveness, safety, or future sales from this excerpt alone.

Analyst inference

What to watch

  1. Look for complete published results across all four cohorts, including response measures, event-free survival, safety, and follow-up, since the supplied article excerpt reports only one group’s response rates. Analyst inference
  2. Watch for any announced next clinical studies or regulatory steps; the article describes a Phase 2 trial and journal publication, not approval or a confirmed development timetable. Analyst inference
  3. A major pathologic response means 10% or less viable tumor remained at surgery; a pathologic complete response means no viable tumor remained, according to the article. Confirmed

Evidence

  • Original source link unavailable